[go: up one dir, main page]

WO2010020766A3 - Polypeptides de fusion d'interleukine - Google Patents

Polypeptides de fusion d'interleukine Download PDF

Info

Publication number
WO2010020766A3
WO2010020766A3 PCT/GB2009/002004 GB2009002004W WO2010020766A3 WO 2010020766 A3 WO2010020766 A3 WO 2010020766A3 GB 2009002004 W GB2009002004 W GB 2009002004W WO 2010020766 A3 WO2010020766 A3 WO 2010020766A3
Authority
WO
WIPO (PCT)
Prior art keywords
fusion polypeptides
polypeptides
interleukin fusion
interleukin
dimers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2009/002004
Other languages
English (en)
Other versions
WO2010020766A2 (fr
Inventor
Peter Artymiuk
Richard Ross
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asterion Ltd
Original Assignee
Asterion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asterion Ltd filed Critical Asterion Ltd
Publication of WO2010020766A2 publication Critical patent/WO2010020766A2/fr
Publication of WO2010020766A3 publication Critical patent/WO2010020766A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des polypeptides et des dimères de fusion d'interleukine; des molécules d'acides nucléiques codant pour lesdits polypeptides et des méthodes de traitement utilisant lesdits polypeptides/dimères.
PCT/GB2009/002004 2008-08-21 2009-08-17 Polypeptides de fusion d'interleukine Ceased WO2010020766A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9082508P 2008-08-21 2008-08-21
GB0815216.7 2008-08-21
GB0815216A GB0815216D0 (en) 2008-08-21 2008-08-21 Interleukin
US61/090,825 2008-08-21

Publications (2)

Publication Number Publication Date
WO2010020766A2 WO2010020766A2 (fr) 2010-02-25
WO2010020766A3 true WO2010020766A3 (fr) 2010-07-29

Family

ID=39812328

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2009/002004 Ceased WO2010020766A2 (fr) 2008-08-21 2009-08-17 Polypeptides de fusion d'interleukine

Country Status (2)

Country Link
GB (1) GB0815216D0 (fr)
WO (1) WO2010020766A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8734774B2 (en) 2010-04-02 2014-05-27 University Of Rochester Protease activated cytokines
WO2013074489A1 (fr) 2011-11-14 2013-05-23 Emory University Conjugués de gm-csf et d'il-7, compositions en contenant et méthodes associées
WO2013184938A2 (fr) * 2012-06-08 2013-12-12 Alkermes. Inc. Polypeptides de fusion comprenant des lieurs polypeptides à domaine mucin
MA40094B1 (fr) * 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
CN109689694B (zh) * 2016-05-19 2022-11-22 通用医疗公司 与其受体IL-2Rβ结合的IL2作为用来增强自然杀伤细胞和调节性T细胞活性的平台
IL322309A (en) 2017-05-24 2025-09-01 Novartis Ag IL2 antibody grafted proteins and methods of use in cancer treatment
EP3768700A1 (fr) 2018-03-23 2021-01-27 Kite Pharma, Inc. Protéines transmembranaires chimériques et leurs utilisations
US11359000B2 (en) * 2018-03-28 2022-06-14 Bristol-Myers Squibb Company Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use
MX2020012252A (es) 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de interleucina 12 activables y metodos de uso de los mismos.
CN113840832A (zh) 2018-05-14 2021-12-24 狼人治疗公司 可活化白介素-2多肽及其使用方法
WO2020102728A1 (fr) 2018-11-16 2020-05-22 Neoimmunetech, Inc. Méthode de traitement d'une tumeur au moyen de l'association de la protéine il-7 et d'un inhibiteur de point de contrôle immunitaire
EP3969035A4 (fr) 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. Groupes caractéristiques de séparation, procédés et utilisation associés
CN114450297A (zh) * 2019-07-12 2022-05-06 普罗维瓦疗法香港有限公司 Il-2组合物及其使用方法
WO2021097376A1 (fr) 2019-11-14 2021-05-20 Werewolf Therapeutics, Inc. Polypeptides de cytokine activables et leurs méthodes d'utilisation
US20210188934A1 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
JP2023512456A (ja) 2020-01-13 2023-03-27 ネオイミューンテック， インコーポレイテッド Ｉｌ－７タンパク質と二重特異性抗体の組み合わせで腫瘍を治療する方法
KR20220137630A (ko) 2020-02-05 2022-10-12 워싱턴 유니버시티 Il-7 단백질과 car-보유 면역 세포의 조합물로 고형 종양을 치료하는 방법
KR20230098201A (ko) 2020-10-26 2023-07-03 네오이뮨텍, 인코퍼레이티드 줄기 세포 동원의 유도 방법
WO2022094475A1 (fr) 2020-11-02 2022-05-05 Neoimmunetech, Inc. Utilisation de l'interleukine-7 pour le traitement du coronavirus
JP2023549112A (ja) 2020-11-05 2023-11-22 ネオイミューンテック， インコーポレイテッド Ｉｌ－７タンパク質とヌクレオチドワクチンの組み合わせで腫瘍を治療する方法
AU2022241762A1 (en) 2021-03-24 2023-09-14 Mural Oncology, Inc. Upar antibodies and fusion proteins with the same
TW202317623A (zh) * 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
WO2023121254A1 (fr) * 2021-12-20 2023-06-29 한양대학교 산학협력단 Protéine de fusion de l'interleukine-2, son procédé de préparation et composition pharmaceutique la comprenant
WO2023130081A1 (fr) 2021-12-30 2023-07-06 Neoimmunetech, Inc. Procédé de traitement d'une tumeur avec une combinaison d'une protéine il-7 et d'un antagoniste du vegf
WO2024102722A1 (fr) 2022-11-07 2024-05-16 Neoimmunetech, Inc. Procédés de traitement d'une tumeur avec un promoteur mgmt non méthylé
WO2025021144A1 (fr) * 2023-07-25 2025-01-30 TJ Biopharma (Shanghai) Co., Ltd. Protéines de fusion d'interféron masquées et leurs utilisations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032141A1 (fr) * 1997-12-19 1999-07-01 Applied Research Systems Ars Holding N.V. Complexe ifnar2/ifn
WO2003059376A1 (fr) * 2001-12-31 2003-07-24 Yeda Research And Development Co. Ltd. Utilisation d'une chimere de il6r/il6 pour la regeneration des cellules nerveuses
WO2006061219A2 (fr) * 2004-12-09 2006-06-15 Merck Patent Gmbh Variants de l'il-7 a immunogenicite reduite
WO2009019456A1 (fr) * 2007-08-08 2009-02-12 Asterion Limited Protéines de fusion d'interféron

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032141A1 (fr) * 1997-12-19 1999-07-01 Applied Research Systems Ars Holding N.V. Complexe ifnar2/ifn
WO2003059376A1 (fr) * 2001-12-31 2003-07-24 Yeda Research And Development Co. Ltd. Utilisation d'une chimere de il6r/il6 pour la regeneration des cellules nerveuses
WO2006061219A2 (fr) * 2004-12-09 2006-06-15 Merck Patent Gmbh Variants de l'il-7 a immunogenicite reduite
WO2009019456A1 (fr) * 2007-08-08 2009-02-12 Asterion Limited Protéines de fusion d'interféron

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PALMER MEGAN J ET AL: "Interleukin-7 receptor signaling network: An integrated systems perspective", April 2008, CELLULAR & MOLECULAR IMMUNOLOGY, VOL. 5, NR. 2, PAGE(S) 79-89, ISSN: 1672-7681, XP002566080 *
VALERIO A ET AL: "SOLUBLE INTERLEUKIN-6 (IL-6) RECEPTOR/IL-6 FUSION PROTEIN ENHANCES IN VITRO DIFFERENTIATION OF PURIFIED RAT OLIGODENDROGLIAL LINEAGE CELLS", MOLECULAR AND CELLULAR NEUROSCIENCES, SAN DIEGO, US, vol. 21, 1 January 2002 (2002-01-01), pages 602 - 615, XP001208544, ISSN: 1044-7431 *
WILKINSON IAN R ET AL: "A ligand-receptor fusion of growth hormone forms a dimer and is a potent long-acting agonist", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 13, no. 9, 1 September 2007 (2007-09-01), pages 1108 - 1113, XP009089546, ISSN: 1078-8956 *

Also Published As

Publication number Publication date
WO2010020766A2 (fr) 2010-02-25
GB0815216D0 (en) 2008-09-24

Similar Documents

Publication Publication Date Title
WO2010020766A3 (fr) Polypeptides de fusion d'interleukine
ZA202308845B (en) Cx3cr1-binding polypeptides
WO2011079902A3 (fr) Matériaux biologiques et utilisations de ceux-ci
GB201020995D0 (en) Biological materials and uses thereof
WO2010120514A3 (fr) Protéines liant des antigènes comprenant des échafaudages protéiniques internes recombinants
ZA200904684B (en) Enzymes for the treatment of lignocellulosics, nucleic acids encoding them and methods for making and using them
WO2011063308A3 (fr) Variants de bêta-glucosidase à propriétés améliorées
WO2013040093A3 (fr) Compositions de peptide-2 de type glucagon et leurs procédés de fabrication et d'utilisation
MX349630B (es) Alfa-amilasas.
WO2012109373A3 (fr) Traitement de l'arthrose et de la douleur
SI3536703T1 (sl) Konsenzni prostatični antigeni, molekule nukleinske kisline, ki jih kodirajo in uporabe le-teh
WO2013152351A3 (fr) Polypeptides de fusion et procédés pour les utiliser
WO2011039368A3 (fr) Molécules de liaison à dll4
EA201390666A1 (ru) Cxcr2-связывающие полипептиды
HK1213194A1 (zh) 用於新型的结合蛋白质pcsk9
WO2009019441A3 (fr) Facteur de stimulation des colonies de granulocytes
WO2011017330A8 (fr) Formulations de polypeptide concentrées à viscosité réduite
WO2010001134A3 (fr) Polypeptides de fusion de l'insuline
WO2012031137A3 (fr) Virus de la stomatite vésiculaire
EP2270145A4 (fr) Nouvelle protéine capable de se fixer à l acide hyaluronique et méthode pour mesurer l acide hyaluronique utilisant cette protéine
WO2013040517A3 (fr) Immunothérapie et diagnostic de la mucormycose au moyen de coth
WO2010108182A3 (fr) Production de protéines de recombinaison dans des ciliés et leurs utilisations
WO2011011630A3 (fr) Biocatalyseurs de nitrilase
WO2010040736A3 (fr) Séquences d’acides aminés dirigées contre le récepteur il18 et/ou il-18 et polypeptides comprenant ces séquences pour traiter des maladies et/ou des troubles associés une signalisation à médiation il-18
WO2008106662A3 (fr) Nitrilases, acides nucléiques les codant et procédés de fabrication et d'utilisation de ceux-ci

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09784942

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09784942

Country of ref document: EP

Kind code of ref document: A2